Obstacles and innovations of macrocyclic drug development
Drug Target Review
JANUARY 16, 2025
Phase III trials for MK-0616 commenced in the second half of 2023. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. Cyclic Peptide Design, Chapter 2: Strategies to Enhance Metabolic Stabilities. These drugs, including grazoprevir and vaniprevir, were the result of macrocyclisation of acyclic precursors.
52 
Let's personalize your content